A phase II study of icotinib and whole-brain radiotherapy in Chinese patients with brain metastases from non-small cell lung cancer

@article{Fan2015API,
  title={A phase II study of icotinib and whole-brain radiotherapy in Chinese patients with brain metastases from non-small cell lung cancer},
  author={Yun Fan and Zhiyu Huang and Luo Fang and Lulu Miao and Lei Gong and Haifeng Yu and Haiyan Yang and T Lei and Weimin Mao},
  journal={Cancer Chemotherapy and Pharmacology},
  year={2015},
  volume={76},
  pages={517-523}
}
AbstractPurpose Icotinib is a new first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. A phase II study was conducted to evaluate the efficacy and safety of icotinib in combination with whole-brain radiotherapy (WBRT) in Chinese NSCLC patients with brain metastases (BMs); the cerebrospinal fluid (CSF)/plasma concentrations of icotinib were also investigated.MethodsEligible patients had BMs from NSCLC, regardless of the EGFR status. Icotinib was administered at… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 14 CITATIONS

Role of epidermal growth factor receptor in lung cancer and targeted therapies.

  • American journal of cancer research
  • 2017
VIEW 6 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

References

Publications referenced by this paper.
SHOWING 1-10 OF 22 REFERENCES